With box warnings

Without box warnings

Branded

Generic

4 results

kalydeco
(ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: KALYDECO is indicated for the treatment of cystic fibrosis in patients aged 1 month and older with at least one responsive CFTR gene mutation. If the mutation is unknown, an FDA-cleared test should be used to identify it.
orkambi
(lumacaftor and ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: ORKAMBI is indicated for the treatment of cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Efficacy and safety have not been established in other CF genotypes. Testing for the mutation is recommended if unknown.
symdeko
(Tezacaftor and Ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: SYMDEKO is indicated for treating cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or have a responsive CFTR mutation, as determined by in vitro data or clinical evidence. Testing is recommended for patients with an unknown genotype.
trikafta
(Elexacaftor, Tezacaftor, and Ivacaftor)
Vertex Pharmaceuticals Incorporated
Usage: TRIKAFTA is indicated for treating cystic fibrosis in patients aged 2 years and older with at least one F508del mutation in the CFTR gene, or other responsive CFTR mutations verified by clinical or laboratory data. An FDA-cleared CF mutation test is recommended if the genotype is unknown.

Cystic Fibrosis Transmembrane Conductance Regulator Potentiator class drugs

kalydeco